Hill-Rom Holdings Inc (NYSE:HRC) had its price target reduced by Needham & Company LLC from $95.00 to $93.00 in a report published on Friday, Marketbeat.com reports. They currently have a buy rating on the medical technology company’s stock.

Several other research firms also recently issued reports on HRC. Stifel Nicolaus increased their price objective on shares of Hill-Rom Holdings from $70.00 to $84.00 and gave the company a buy rating in a report on Monday, May 1st. Zacks Investment Research raised shares of Hill-Rom Holdings from a hold rating to a buy rating and set a $87.00 price objective on the stock in a report on Friday, June 2nd. Barclays PLC increased their price objective on shares of Hill-Rom Holdings from $80.00 to $86.00 and gave the company an overweight rating in a report on Friday, June 9th. ValuEngine raised shares of Hill-Rom Holdings from a hold rating to a buy rating in a report on Friday, June 2nd. Finally, Morgan Stanley increased their price objective on shares of Hill-Rom Holdings from $85.00 to $90.00 and gave the company an overweight rating in a report on Friday, June 30th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $88.17.

Shares of Hill-Rom Holdings (NYSE HRC) traded up 0.76% during mid-day trading on Friday, reaching $75.09. 102,612 shares of the company’s stock were exchanged. Hill-Rom Holdings has a 1-year low of $50.50 and a 1-year high of $84.65. The company’s 50 day moving average is $80.68 and its 200 day moving average is $72.04. The stock has a market capitalization of $4.95 billion, a PE ratio of 43.76 and a beta of 1.23.

Hill-Rom Holdings (NYSE:HRC) last posted its quarterly earnings data on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.01. The business had revenue of $689.10 million for the quarter, compared to the consensus estimate of $695.50 million. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. Equities research analysts anticipate that Hill-Rom Holdings will post $3.86 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/needham-company-llc-lowers-hill-rom-holdings-inc-nysehrc-price-target-to-93-00/1465858.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 15th will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Thursday, September 14th. Hill-Rom Holdings’s dividend payout ratio is currently 41.62%.

In other news, SVP Andreas G. Frank sold 10,660 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total value of $838,089.20. Following the transaction, the senior vice president now directly owns 28,988 shares of the company’s stock, valued at $2,279,036.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Paul Sherwood Johnson sold 2,078 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $72.30, for a total transaction of $150,239.40. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in Hill-Rom Holdings during the fourth quarter valued at $235,000. Foundry Partners LLC increased its position in Hill-Rom Holdings by 3.3% in the first quarter. Foundry Partners LLC now owns 188,507 shares of the medical technology company’s stock valued at $13,309,000 after buying an additional 6,039 shares in the last quarter. Copper Rock Capital Partners LLC increased its position in Hill-Rom Holdings by 18.7% in the first quarter. Copper Rock Capital Partners LLC now owns 687,768 shares of the medical technology company’s stock valued at $48,838,000 after buying an additional 108,459 shares in the last quarter. Bank of Montreal Can increased its position in Hill-Rom Holdings by 294.3% in the first quarter. Bank of Montreal Can now owns 987,030 shares of the medical technology company’s stock valued at $69,684,000 after buying an additional 736,681 shares in the last quarter. Finally, Capstone Asset Management Co. increased its position in Hill-Rom Holdings by 2.0% in the first quarter. Capstone Asset Management Co. now owns 7,515 shares of the medical technology company’s stock valued at $531,000 after buying an additional 150 shares in the last quarter. 83.94% of the stock is currently owned by hedge funds and other institutional investors.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.